Pharma
GSK India targets doubling revenue to ₹8,000 crore by FY30 on new growth drivers
BullishPharma
GSK India aims to double its revenue to approximately ₹8,000 crore by fiscal 2030, driven by a strategic focus on oncology and adult vaccines. The company projects its oncology business could reach ₹750-1,000 crore within five years, a significant increase from its current negligible contribution. Key upcoming launches within the next 12 months include the cancer drugs Blenrep and Omjjara, along with the RSV vaccine Arexvy.
Premium Signal
Subscribe to ResearchAmp Sherpa for full access to all intelligence signals, including body content, filters, and unlimited scrolling.
View Plans